Is central benzodiazepine receptor imaging useful for the identification of epileptogenic foci in localization-related epilepsies?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 2, 2003, Pages 325-328

  Goethals, Ingeborg ^a   Wiele, Christophe ^a   Boon, Paul ^a   Dierckx, Rudi ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Epileptogenic foci; FDG PET; Flumazenil; Iomazenil; Partial epilepsy syndromes

Indexed keywords

BENZODIAZEPINE RECEPTOR; FLUMAZENIL; FLUORODEOXYGLUCOSE F 18; GLUCOSE; IOMAZENIL;

BRAIN REGION; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; EPILEPTIC FOCUS; FOCAL EPILEPSY; GLUCOSE METABOLISM; HUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0038515237     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-1083-z     Document Type: Review

References (40)

1. Berkovic SF, McIntosh AM, Kalnins RM, Jackson GD, Fabinyi GC, Brazenor GA, Bladin PF, Hopper JL. Preoperative MRI predicts outcome of temporal lobectomy: an actuarial analysis. Neurology 1995; 45:1358-1363.
2. Babb TL, Brown WJ, Pretorius J, Davenport C, Lieb JP, Crandall PH. Temporal lobe volumetric cell densities in temporal lobe epilepsy. Epilepsia 1984; 25:729-740.
3. Van Paesschen W, Connelly A, King MD, Jackson GD, Duncan JS. The spectrum of hippocampal sclerosis: a quantitative magnetic resonance imaging study. Ann Neurol 1997; 41:41-51.
4. Zentner J, Hufnagel A, Ostertun B, Wolf HK, Behrens E, Campos MG, Solymosi L, Elger CE, Wiestler OD, Schramm J. Surgical treatment of extratemporal epilepsy: clinical, radiologic, and histopathologic findings in 60 patients. Epilepsia 1996; 37:1072-1080.
5. Arnold S, Schlaug G, Niemann H, Ebner A, Luders H, Witte OW, Seitz RJ. Topography of interictal glucose hypometabolism in unilateral mesiotemporal epilepsy. Neurology 1996; 46:1422-1430.
6. Savic I, Ingvar M, Stone-Elander S. Comparison of [11C]flumazenil and [18F]FDG as PET markers of epileptic foci. J Neurol Neurosurg Psychiatry 1993; 56:615-621.
7. Henry TR, Frey KA, Sackellares JC, Gilman S, Koeppe RA, Brunberg JA, Ross DA, Berent S, Young AB, Kuhl DE. In vivo cerebral metabolism and central benzodiazepine-receptor binding in temporal lobe epilepsy. Neurology 1993; 43: 1998-2006.
8. Henry TR, Mazziotta JC, Engel J Jr. Interictal metabolic anatomy of mesial temporal lobe epilepsy. Arch Neurol 1993; 50: 582-589.
9. da Silva EA, Chugani DC, Muzik O, Chugani HT. Identification of frontal lobe epileptic foci in children using positron emission tomography. Epilepsia 1997; 38:1198-1208.
10. Theodore WH, Dorwart R, Holmes M, Porter RJ, DiChiro G. Neuroimaging in refractory partial seizures: comparison of PET, CT, and MRI. Neurology 1986; 36:750-759.
11. Swartz BE, Halgren E, Delgado-Escueta AV, Mandelkern M, Gee M, Quinones N, Blahd WH, Repchan J. Neuroimaging in patients with seizures of probable frontal lobe origin. Epilepsia 1989; 30:547-558.
12. Duncan JS, Koepp MJ. PET: central benzodiazepine neuroreceptor mapping in localization-related epilepsies. Adv Neurol 2000; 83:131-136.
13. Pennell PB. PET: cholinergic neuroreceptor mapping. Adv Neurol 2000; 83:157-163.
14. Koepp MJ, Duncan JS. PET: opiate neuroreceptor mapping. Adv Neurol 2000; 83:145-156.
15. Olsen RW, McCabe RT, Wamsley JK. GABAA receptor subtypes: autoradiographic comparison of GABA, benzodiazepine, and convulsant binding sites in the rat central nervous system. J Chem Neuroanat 1990; 3:59-76.
16. Torizuka K, Uemura K, Toru M, Shinohara Y, Nishimura T, Yonekura Y, Nakagawara J, Matsuda H, Sakai F, Matsuda K, Fukuyama H, Morimoto K. [A phase 3 clinical trial of 123Iiomazenil, a new central-type benzodiazepine receptor imaging agent (Part 1) - report on clinical usefulness in diagnosis of various brain diseases]. Kaku Igaku 1996; 33:293-301.
17. Savic I, Persson A, Roland P, Pauli S, Sedvall G, Widen L. In vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci. Lancet 1988; 2:863-866.
18. Hammers A, Koepp MJ, Labbe C, Brooks DJ, Thom M, Cunningham VJ, Duncan JS. Neocortical abnormalities of [11C]-flumazenil PET in mesial temporal lobe epilepsy. Neurology 2001; 56:897-906.
19. Torizuka K, Uemura K, Toru M, Shinohara Y, Nishimura T, Yonekura Y, Nakagawara J, Matsuda H, Sakai F, Matsuda K, Fukuyama H, Morimoto K. [A phase 3 clinical trial of 123I-iomazenil, a new central-type benzodiazepine receptor imaging agent (Part 3) - Report on clinical usefulness in epilepsy]. Kaku Igaku 1996; 33:319-328.
20. Szelies B, Weber-Luxenburger G, Pawlik G, Kessler J, Holthoff V, Mielke R, Herholz K, Bauer B, Wienhard K, Heiss WD. MRI-guided flumazenil- and FDG-PET in temporal lobe epilepsy. Neuroimage 1996; 3: 109-118.
21. Debets RM, Sadzot B, van Isselt JW, Brekelmans GJ, Meiners LC, van Huffelen AO, Franck G, van Veelen CW. Is 11C-flumazenil PET superior to 18FDG PET and 123I-iomazenil SPECT in presurgical evaluation of temporal lobe epilepsy? J Neurol Neurosurg Psychiatry 1997; 62:141-150.
22. Lamusuo S, Ruottinen HM, Knuuti J, Harkonen R, Ruotsalainen U, Bergman J, Haaparanta M, Solin O, Mervaala E, Nousiainen U, Jaaskelainen S, Ylinen A, Kalviainen R, Rinne JK, Vapalahti M, Rinne JO. Comparison of [18F]FDG-PET, [99mTc]-HMPAO-SPECT, and [123I]-iomazenil-SPECT in localising the epileptogenic cortex. J Neurol Neurosurg Psychiatry 1997; 63:743-748.
23. Sjoholm H, Rosen I, Elmqvist D. Role of I-123-iomazenil SPECT imaging in drug resistant epilepsy with complex partial seizures. Acta Neurol Scand 1995; 92:41-48.
24. van Huffelen AC, van Isselt JW, van Veelen CW, van Rijk PP, van Bentum AM, Dive D, Maquet P, Franck G, Velis DN, van Emde BW. Identification of the side of epileptic focus with 123I-Iomazenil SPECT. A comparison with 18FDG-PET and ictal EEG findings in patients with medically intractable complex partial seizures. Acta Neurochir Suppl (Wien) 1990; 50: 95-99.
25. Tanaka F, Yonekura Y, Ikeda A, Terada K, Mikuni N, Nishizawa S, Ishizu K, Okazawa H, Hattori N, Shibasaki H, Konishi J, Onishi Y. Presurgical identification of epileptic foci with iodine-123 iomazenil SPET: comparison with brain perfusion SPET and FDG PET. Eur J Nucl Med 1997; 24:27-34.
26. Koepp MJ, Richardson MP, Brooks DJ, Poline JB, Van Paesschen W, Friston KJ, Duncan JS. Cerebral benzodiazepine receptors in hippocampal sclerosis. An objective in vivo analysis. Brain 1996; 119 Pt 5:1677-1687.
27. Koepp MJ, Labbe C, Richardson MP, Brooks DJ, Van Paesschen W, Cunningham VJ, Duncan JS. Regional hippocampal [11C]flumazenil PET in temporal lobe epilepsy with unilateral and bilateral hippocampal sclerosis. Brain 1997; 120 Pt 10:1865-1876.
28. Koepp MJ, Richardson MP, Labbe C, Brooks DJ, Cunningham VJ, Ashburner J, Van Paesschen W, Revesz T, Duncan JS. 11C-flumazenil PET, volumetric MRI, and quantitative pathology in mesial temporal lobe epilepsy. Neurology 1997; 49:764-773.
29. Sisodiya SM, Moran N, Free SL, Kitchen ND, Stevens JM, Harkness WF, Fish DR, Shorvon SD. Correlation of widespread preoperative magnetic resonance imaging changes with unsuccessful surgery for hippocampal sclerosis. Ann Neurol 1997; 41:490-496.
30. Koepp MJ, Hammers A, Labbe C, Woermann FG, Brooks DJ, Duncan JS. 11C-flumazenil PET in patients with refractory temporal lobe epilepsy and normal MRI. Neurology 2000; 54:332-339.
31. Richardson MP, Koepp MJ, Brooks DJ, Fish DR, Duncan JS. Benzodiazepine receptors in focal epilepsy with cortical dysgenesis: an 11C-flumazenil PET study. Ann Neurol 1996; 40:188-198.
32. Richardson MP, Friston KJ, Sisodiya SM, Koepp MJ, Ashburner J, Free SL, Brooks DJ, Duncan JS. Cortical grey matter and benzodiazepine receptors in malformations of cortical development. A voxel-based comparison of structural and functional imaging data. Brain 1997; 120 Pt 11:1961-1973.
33. Ryvlin P, Bouvard S, Le Bars D, De Lamerie G, Gregoire MC, Kahane P, Froment JC, Mauguiere F. Clinical utility of flumazenil-PET versus [18F]fluorodeoxyglucose-PET and MRI in refractory partial epilepsy. A prospective study in 100 patients. Brain 1998; 121 Pt 11:2067-2081.
34. Savic I, Thorell JO, Roland P. [11C]flumazenil positron emission tomography visualizes frontal epileptogenic regions. Epilepsia 1995; 36:1225-1232.
35. Muzik O, da Silva EA, Juhasz C, Chugani DC, Shah J, Nagy F, Canady A, von Stockhausen HM, Herholz K, Gates J, Frost M, Ritter F, Watson C, Chugani HT. Intracranial EEG versus flumazenil and glucose PET in children with extratemporal lobe epilepsy. Neurology 2000; 54:171-179.
36. Juhasz C, Chugani DC, Muzik O, Shah A, Shah J, Watson C, Canady A, Chugani HT. Relationship of flumazenil and glucose PET abnormalities to neocortical epilepsy surgery outcome. Neurology 2001; 56:1650-1658.
37. Ryvlin P, Guénot M, Isnard J, Sindou M, et al. The role of the temporopolar cortex in temporal lobe epilepsy [abstract]. Stereotact Funct Neurosurg 1997; 67:143.
38. Morrell F. Secondary epileptogenesis in man. Arch Neurol 1985; 42:318-335.
39. Savic I, Blomqvist G, Halldin C, Litton JE, Gulyas B. Regional increases in [11C]flumazenil binding after epilepsy surgery. Acta Neurol Scand 1998; 97:279-286.
40. Niimura K, Muzik O, Chugani DC, Shen C, Chugani HT. [11C]flumazenil PET: activity images versus parametric images for the detection of neocortical epileptic foci. J Nucl Med 1999; 40:1985-1991.